FCMT
AZN icon

Founders Capital Management (Texas)’s AstraZeneca AZN Stock Holding History

Founders Capital Management (Texas)’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-34
Closed -$4.61K – 382
2023
Q3 		$4.61K Buy
+34
New +$4.64K ﹤0.01% 345

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Founders Capital Management (Texas)'s AZN Position: Q4 2023 in Review

Founders Capital Management (Texas) sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 34 shares — an estimated $4.61K sold.

Founders Capital Management (Texas) first reported a position in AZN in Q3 2023 and held it in 1 quarter. The position peaked at $4.61K in Q3 2023. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

  • Founders Capital Management (Texas) reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
  • Founders Capital Management (Texas) sold 34 AstraZeneca shares in Q4 2023, an estimated $4.61K.
  • Founders Capital Management (Texas) first reported a position in AstraZeneca in Q3 2023 and held it in 1 quarter.
  • Founders Capital Management (Texas)'s AstraZeneca position peaked at $4.61K in Q3 2023.
  • 1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Founders Capital Management (Texas)'s 13F filing for Q4 2023, filed 8 Jan 2024.